NLRC5 and osteosarcoma: These concepts, supported predominantly by preclinical data and not yet validated in osteosarcoma-specific trials, align with single-cell chromatin evidence of reversible repression at HLA/NLRC5 regulatory elements and motivate biomarker-guided exploration in early-phase studies.